Technical Analysis for XNCR - Xencor, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical XNCR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 16 | 20 DMA Resistance | Bearish | 0.00% |
| Jan 16 | MACD Bearish Signal Line Cross | Bearish | 0.00% |
| Jan 15 | 20 DMA Resistance | Bearish | 0.23% |
| Jan 15 | Doji - Bullish? | Reversal | 0.23% |
| Jan 15 | Down 3 Days in a Row | Weakness | 0.23% |
| Jan 15 | Down 4 Days in a Row | Weakness | 0.23% |
| Jan 14 | Fell Below 200 DMA | Bearish | -0.32% |
| Jan 14 | Fell Below 20 DMA | Bearish | -0.32% |
| Jan 14 | Fell Below 50 DMA | Bearish | -0.32% |
| Jan 14 | MACD Bearish Centerline Cross | Bearish | -0.32% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-05
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through XmAb technology platform. The company's engineered antibodies that are in development include XmAb5871, a B-cell inhibitor that is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor to treat severe asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more XNCR news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 48.38 |
| 52 Week Low | 20.16 |
| Average Volume | 192,916 |
| 200-Day Moving Average | 37.2881 |
| 50-Day Moving Average | 37.3106 |
| 20-Day Moving Average | 35.2405 |
| 10-Day Moving Average | 36.475 |
| Average True Range | 2.0308 |
| ADX | 15.57 |
| +DI | 15.8544 |
| -DI | 24.2714 |
| Chandelier Exit (Long, 3 ATRs ) | 33.2326 |
| Chandelier Exit (Short, 3 ATRs ) | 37.3124 |
| Upper Bollinger Band | 38.9969 |
| Lower Bollinger Band | 31.4841 |
| Percent B (%b) | 0.41 |
| BandWidth | 21.318653 |
| MACD Line | -0.2843 |
| MACD Signal Line | -0.2483 |
| MACD Histogram | -0.036 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.62 Billion |
| Num Shares | 46.9 Million |
| EPS | -0.87 |
| Price-to-Earnings (P/E) Ratio | -39.74 |
| Price-to-Sales | 29.06 |
| Price-to-Book | 3.08 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 36.69 | ||||
| Resistance 3 (R3) | 36.73 | 36.07 | 36.33 | ||
| Resistance 2 (R2) | 36.07 | 35.53 | 36.05 | 36.21 | |
| Resistance 1 (R1) | 35.32 | 35.20 | 35.70 | 35.28 | 36.10 |
| Pivot Point | 34.66 | 34.66 | 34.85 | 34.64 | 34.66 |
| Support 1 (S1) | 33.91 | 34.12 | 34.29 | 33.87 | 33.04 |
| Support 2 (S2) | 33.25 | 33.79 | 33.23 | 32.93 | |
| Support 3 (S3) | 32.50 | 33.25 | 32.81 | ||
| Support 4 (S4) | 32.46 |
